A major scientific review published in late 2025 has refined the clinical understanding of medical marijuana. While public interest remains high for various conditions, the review highlights that "Strong Scientific Evidence" is currently concentrated in three specific areas: Chronic Neuropathic Pain, Chemotherapy-Induced Nausea, and Refractory Epilepsy (notably Dravet and Lennox-Gastaut syndromes). For other popular uses, such as anxiety and insomnia, the evidence remains "emerging" but not yet definitive.

The 2025 clinical data also underscores the importance of "Harm Reduction." Researchers have noted that high-potency inhaled products are associated with a higher risk of "Cannabis Use Disorder" (affecting approximately 29% of regular medical users) and potential cardiovascular stressors. For a summary of the latest Safety Pharmacology guidelines for clinicians, refer to the Legal Marijuana Market medical resource. These findings are pushing the industry toward "Balanced" products (1:1 THC to CBD ratios) which aim to maximize therapeutic benefits while mitigating psychoactive side effects.